Home › Funds › DAVIDSON INVESTMENT ADVISORS › VRTX

DAVIDSON INVESTMENT ADVISORS position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

DAVIDSON INVESTMENT ADVISORS reported holding 47,760 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.0M, representing 1.04% of its reported portfolio and ranking #28 among its reported holdings. DAVIDSON INVESTMENT ADVISORS has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)47.76K sh
Reported value held$24.97M
Portfolio Weight1.04%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How DAVIDSON INVESTMENT ADVISORS's VRTX position evolved

DAVIDSON INVESTMENT ADVISORS first disclosed a stake in VRTX in Q3 2023 at 62,911 shares (US$21.9M). The position peaked in Q1 2025 at 62,883 shares, worth US$30.5M. Across 13 filings, DAVIDSON INVESTMENT ADVISORS increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 47,760 shares valued at US$25.0M — a reduction of -950 shares quarter over quarter.. Notable position changes include a 29% trim in Q4 2023 (shares rose 2% over the following quarter), a 26% increase in Q4 2024 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 62.91K $21.88M New
Q4 2023 44.52K $18.11M Reduce
Q1 2024 45.69K $19.10M Add
Q2 2024 46.34K $21.72M Add
Q3 2024 48.53K $22.57M Add
Q4 2024 61.16K $24.63M Add
Q1 2025 62.88K $30.49M Add
Q2 2025 63.69K $28.35M Add
Q3 2025 62.42K $24.45M Reduce
Q4 2025 64.23K $29.12M Add
Q1 2026 51.22K $22.87M Reduce
Q2 2026 48.71K $24.20M Reduce
Q3 2026 47.76K $24.97M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has DAVIDSON INVESTMENT ADVISORS held VRTX?

DAVIDSON INVESTMENT ADVISORS has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is DAVIDSON INVESTMENT ADVISORS's current position in VRTX?

As of Q3 2026, DAVIDSON INVESTMENT ADVISORS holds 47.76K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $24.97M, representing 1.04% of its reported portfolio and ranking #28.

Has DAVIDSON INVESTMENT ADVISORS been buying or selling VRTX?

In the latest 13F filing (Q3 2026), DAVIDSON INVESTMENT ADVISORS reduced its position in VRTX. The position peaked in Q1 2025 at 62.88K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.